Duchenne muscular dystrophy-focused Dyne Therapeutics is back on track to move its first asset into the clinic in the coming weeks after the FDA lifted a clinical hold on the drug. The agency hit the ...

Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical ...

Dyne Therapeutics, Inc. (NASDAQ:DYN) stock is trading lower after the company announced on Tuesday that it had revised the ongoing Registrational Expansion Cohort in the Phase 1/2 ACHIEVE trial for ...

Dyne Therapeutics is a clinical-stage biotech. The company focuses on rare genetic disorders. It has seven programs in its pipeline, but only two are in clinical trials. Dyne focuses on treating ...

Shares of Dyne Therapeutics fell on Tuesday after the company revised the primary endpoint in the registrational expansion cohort of its Achieve trial for DYNE-101, a treatment for myotonic dystrophy ...

Dyne Therapeutics (DYN) has been appearing on more watchlists lately, and it is easy to see why investors might be pausing to assess their next move. With so much energy around biotech innovation, any ...

Jan 3 (Reuters) - Shares of drug developer Dyne Therapeutics (DYN.O), opens new tab jumped 18% on Wednesday after its experimental therapy for a muscle-wasting disorder called Duchenne muscular ...

Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 14 Best Small Cap Stocks to Buy Right Now. On August 25, Raymond James increased the price target on Dyne Therapeutics, Inc. (NASDAQ:DYN) stock from ...

(RTTNews) - Dyne Therapeutics Inc. (DYN), a clinical-stage company developing treatments for genetically driven neuromuscular diseases, is advancing its programs in Myotonic Dystrophy and Duchenne ...

Dyne Therapeutics Inc. shares DYN jumped 40% premarket on Wednesday after the company released new data from trials of two investigational treatments for genetic muscle disorders. The experimental ...